Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC
Primary Purpose
Oropharynx Cancer, Oral Cancer, Hypopharynx Cancer
Status
Completed
Phase
Phase 2
Locations
France
Study Type
Interventional
Intervention
Radiotherapy 62-64 Gy in 5 W (31-32 f. of 2 Gy BID)
Radiotherapy 62-64 Gy in 22-23 D (31-32 f of 2 Gy BID)
CDDP, 5 Fu
Sponsored by
About this trial
This is an interventional treatment trial for Oropharynx Cancer focused on measuring Head and neck squamous cell carcinoma, Radiotherapy, Chemotherapy
Eligibility Criteria
Inclusion Criteria: palpable N2b-c or N3 (UICC 1997) squamous cell carcinoma of the head and neck (oropharynx, oral cavity, hypopharynx or larynx) primary tumor and / or nodal extension strictly inoperable due to the extension of the disease performance status of 0 to 2 (WHO scoring system) renal/liver/cardiac functions and blood counts compatible with the use of CDDP and 5-FU signed inform consent Exclusion Criteria: distant metastasis previous history of cancer previous radiotherapy or chemotherapy
Sites / Locations
- Centre Jean Perrin
- Centre Alexis Vautrin
- Institut Gustave Roussy
Outcomes
Primary Outcome Measures
Event free survival (event = progressive disease or relapse or or death from any cause)
Secondary Outcome Measures
Survival
Toxicity
Full Information
NCT ID
NCT00162708
First Posted
September 9, 2005
Last Updated
September 9, 2005
Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
1. Study Identification
Unique Protocol Identification Number
NCT00162708
Brief Title
Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC
Official Title
A Randomized Trial Evaluating a Very Intense Radiotherapy-Chemotherapy Regimen Versus a Very Accelerated Radiotherapy in Advanced Head and Neck Squamous Cell Carcinoma
Study Type
Interventional
2. Study Status
Record Verification Date
September 2005
Overall Recruitment Status
Completed
Study Start Date
July 1996 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
4. Oversight
5. Study Description
Brief Summary
Altered fractionated radiotherapy and concomitant radio-chemotherapy have been shown to be two possibilities for improving efficacy of radiotherapy in locally advanced head and neck carcinomas. In this multicentric study, we tested the hypothesis that accelerated radiotherapy could be delivered concomitantly with conventional high doses of CDDP-5FU, aiming to improve both local control and on distant metastases as compared to very accelerated radiotherapy.
Detailed Description
Patients with a palpable N2b-c or N3 HNSCC strictly unresectable were randomized to receive either accelerated RT-CT delivering to the primary tumor 62-64 Gy / 5 weeks in 31-32 fractions of 2 Gy BID or very accelerated RT delivering 62-64 Gy in 31-32 fractions of 2 Gy BID and 22-23 days. In the accelerated RT-CT arm, 3 cycles of CDDP 100 mg/m2 were delivered at day 1, 16, 32 and 2 cycles of 5 Fu 1000 mg/m2 day 1 to 5 and 31 to 35. One month after completion of the concomitant RT-CT, 2 additional cycles of CDDP-5FU were given in patients responding (> 50%) to the initial course of RT-CT. The end points were event free survival and survival.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Oropharynx Cancer, Oral Cancer, Hypopharynx Cancer, Larynx Cancer
Keywords
Head and neck squamous cell carcinoma, Radiotherapy, Chemotherapy
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
120 (false)
8. Arms, Groups, and Interventions
Intervention Type
Procedure
Intervention Name(s)
Radiotherapy 62-64 Gy in 5 W (31-32 f. of 2 Gy BID)
Intervention Type
Procedure
Intervention Name(s)
Radiotherapy 62-64 Gy in 22-23 D (31-32 f of 2 Gy BID)
Intervention Type
Drug
Intervention Name(s)
CDDP, 5 Fu
Primary Outcome Measure Information:
Title
Event free survival (event = progressive disease or relapse or or death from any cause)
Secondary Outcome Measure Information:
Title
Survival
Title
Toxicity
10. Eligibility
Sex
All
Minimum Age & Unit of Time
40 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
palpable N2b-c or N3 (UICC 1997) squamous cell carcinoma of the head and neck (oropharynx, oral cavity, hypopharynx or larynx)
primary tumor and / or nodal extension strictly inoperable due to the extension of the disease
performance status of 0 to 2 (WHO scoring system)
renal/liver/cardiac functions and blood counts compatible with the use of CDDP and 5-FU
signed inform consent
Exclusion Criteria:
distant metastasis
previous history of cancer
previous radiotherapy or chemotherapy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jean Bourhis
Organizational Affiliation
Gustave Roussy, Cancer Campus, Grand Paris
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Michel Lapeyre
Organizational Affiliation
Centre Alexis Vautrin
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jacques Tortochaux
Organizational Affiliation
Centre Jean Perrin
Official's Role
Principal Investigator
Facility Information:
Facility Name
Centre Jean Perrin
City
Clermont-Ferrand
Country
France
Facility Name
Centre Alexis Vautrin
City
Nancy
Country
France
Facility Name
Institut Gustave Roussy
City
Villejuif
ZIP/Postal Code
94800
Country
France
12. IPD Sharing Statement
Learn more about this trial
Very Intense Radiotherapy-Chemotherapy Regimen in Advanced HNSCC
We'll reach out to this number within 24 hrs